Nanopharmacology focuses on the design, development, and application of nanoscale materials for medical purposes. At the intersection of nanotechnology and pharmacology, this discipline harnesses the unique properties of nanoparticles to revolutionize drug delivery and therapeutic interventions. Nanoparticles, often ranging in size from 1 to 100 nanometers, offer distinct advantages such as increased surface area, enhanced bioavailability, and targeted delivery to specific cells or tissues. In the realm of pharmaceuticals, nanopharmacology holds the promise of overcoming challenges associated with conventional drug delivery systems, including poor solubility and systemic side effects.
By precisely manipulating the physicochemical properties of nanoparticles, researchers aim to optimize drug formulations, improve therapeutic efficacy, and minimize adverse reactions. This field's potential extends beyond drug delivery, as nanopharmacology also explores diagnostic applications and personalized medicine, showcasing its transformative impact on the future of healthcare. As scientists delve deeper into understanding the intricate interactions at the nanoscale, nanopharmacology emerges as a frontier with vast implications for advancing pharmaceutical science and patient care.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia